228467 Finsbury WWH pp01-pp18 18 06 2013 10:40 Page 01 Financial Highlights 01 Financial Highlights As at As at 31 March 31 March % 2013 2012 Change Share price 1009.0p 795.0p 26.9 Net asset value per share diluted dilution for subscription shares 1089.6p 871.0p 25.1 Net asset value per share basic 1110.2p 909.4p 22.1 Discount of share price to the diluted net asset value per share 7.4% 8.7% n a Year ended Year ended 31 March 31 March 2013 2012 Share price total return 30.9% 18.2% Net asset value per share total return 30.3% 14.4% Benchmark index total return 31.4% 13.4% Dividends per share 16.5p 17.5p Source Morningstar.
The net asset value per share has been diluted for both subscription shares and treasury shares.
Includes the 2012 interim dividend of 17.5p per share which had an ex dividend date of 6 June 2012 and also the 2013 first interim dividend of 7.0p per share which had an ex dividend date of 12 December 2012.
Details of the Companys historic performance can be found on page 11.
PERFORMANCE SINCE LAUNCH TO 31 MARCH 2013 1400 1200 1000 800 600 400 200 100 Apr Mar Mar Mar Mar Mar Mar Mar Mar Mar Mar Mar Mar Mar Mar Mar Mar Mar Mar 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 11 12 13 WWH Net Asset Value total return WWH Share Price total return Benchmark Index total return Rebased to 100 as at 28 April 1995 Source Morningstar, Thomson Reuters and Bloomberg.
With effect from 1 October 2010, the performance of the Company is measured against the MSCI World Health Care Index on a net total return, sterling adjusted basis.
Prior to this date, performance was measured against the Datastream World Pharmaceutical & Biotechnology Index total return, sterling adjusted.
Worldwide Healthcare Trust PLC Annual Report 2013 228467 Finsbury WWH pp01-pp18 18 06 2013 10:40 Page 02 02 Chairmans Statement Chairmans Statement I am delighted to report that during the year ended 31 March 2013, the Companys net asset value per share total return was 30.3% and the share price total return was 30.9%... REVIEW OF THE CAPITAL YEAR AND In implementing our policy of actively managing the share price PERFORMANCE discount we repurchased a total of 2,411,340 ordinary shares for treasury during the year, at a discount greater than 6.0% to the I am delighted to report that during prevailing diluted net asset value per share, at a cost of the year ended 31 March 2013, the 19.2 million including expenses.
In line with the Boards policy, a Companys net asset value per share total of 2,941,518 shares held in treasury at 18 July 2012, the date total return was 30.3% and the of last years Annual General Meeting, were cancelled.
I am pleased share price total return was 30.9%, to report that, during the year and to the date of this report, we both closely tracking the Companys Sir Martin Smith have been able to reissue all of the 378,408 shares bought back benchmark, the MSCI World Health into treasury since the 2012 Annual General Meeting at prices Care Index on a net total return, sterling adjusted basis, which representing no more than a 4.9% discount to the prevailing fully rose by 31.4%.
I should point out that the share price and the diluted cum income net asset value per share, raising 4.0 million net asset value total return generated during the year were of new funds for the Company.
Shareholder approval to renew the enhanced by the change in the Companys dividend payment authority to buy-back both ordinary shares and subscription policy whereby a first interim dividend of 7.0p per share was shares will be sought at the Annual General Meeting.
This extra dividend payment enhanced execution and timing of any share buy-back will continue to be at performance in total return terms by approximately 1.0%.
The the absolute discretion of the Board.
Company has continued to benefit from strong performance from biopharmaceutical companies such as Gilead Sciences I would like to remind shareholders that any shares held in and Onyx Pharmaceuticals, and also from large capitalisation treasury on 17 July 2013, the date of this years Annual General pharmaceutical companies such as Roche Holdings, Pfizer Meeting, will be cancelled.
Further information on the Companys investments The next exercise date for the Companys subscription shares is can be found in the Review of Investments beginning on page 5 31 July 2013 and the exercise price is 699p, where it will remain of this Annual Report.
until the expiry date of the subscription shares on 31 July 2014.
Since the Companys inception in 1995, the total return of the As a result of holders of subscription shares exercising their Companys net asset value per share is 1,150.4%, equivalent to a subscription rights during the year and to the date of this compound annual return of 15.1%.
This compares to a report a total of 4,764,682 new shares were issued, raising cumulative blended benchmark return of 593.8%, equivalent 30.5 million of additional funds for the Company.
to a compound annual return of 11.4%.
During this period the Companys net asset value total return ranked second out of the REVENUE AND DIVIDEND approximately 250 UK Listed Investment Companies I reminded shareholders last year that it remained the Source: Winterflood Securities Limited and Thomson Reuters.
Companys policy to pursue capital growth for shareholders and to pay dividends to the extent required to maintain investment At 31 March 2013, the discount of the Companys share price to trust status, I also confirmed that the Company would in future the diluted net asset value was 7.4% 31 March 2012: 8.7%.
declare two interim dividends per year.
A first interim dividend However, as a result of continued strong performance, at the of 7.0p per share, for the year ended 31 March 2013, was paid on time of writing the discount has narrowed to 1.3%.
The average 11 January 2013 to ordinary shareholders on the register on discount of the share price to the diluted net asset value per 14 December 2012.
The Companys net revenue return for the share during the year was 6.0% which compares to 7.1% during year as a whole has fallen slightly to 7.6 million the previous year.
Worldwide Healthcare Trust PLC Annual Report 2013 228467 Finsbury WWH pp01-pp18 18 06 2013 10:40 Page 03 Chairmans Statement 03 Chairmans Statement continued 2012: 9.5 million due to a reduction in the overall yield from THE ALTERNATIVE INVESTMENT portfolio investments.
The Board has declared a second interim FUND MANAGERS DIRECTIVE dividend of 9.5p per share which, together with the first interim AIFMD dividend already paid, makes a total dividend for the year of The AIFMD is European legislation which will create a European- 16.5p 2012: 17.5p per share which is sufficient to ensure that wide framework for regulating managers of alternative the Company maintains its investment trust status.
Based on the investment funds, which includes investment trusts.
It came current mid-market share price of 1052.0p the total dividend into force in July 2011 with the intention that it be implemented payment for the year represents a yield of 1.6%.
into national legislation by July 2013.
Your Board is currently in The second interim dividend will be payable on 5 July 2013 to the process of complying with this legislation and will keep ordinary shareholders on the register of members on 7 June shareholders informed of developments.
The associated ex-dividend date was 5 June 2013.
OUTLOOK GEARING While the prospects for global economic growth remain mixed, The Companys borrowing requirements are met through a loan with a further year of recession and continued political facility, negotiated on competitive terms, which is repayable on uncertainty expected in the Eurozone, and the Chinese demand, provided by the custodian Goldman Sachs & Co New economy struggling with high energy costs and a deteriorating York.
As at 31 March 2013 a total of 31.4 million of this facility trade balance.
However, there is better news in Japan and also was drawn down, representing 6.2% of the Companys net in the U. S. where, despite automatic budgetary cuts, the US assets.
Your Company has utilised gearing over many years and economy is still expected to grow at 2% this year.
Our the Board believes that the availability of a meaningful gearing Investment Manager continues to believe that the outlook for facility is very useful for a closed end investment company such the healthcare sector is positive and that there is potential for as ours.
The Companys gearing policy is to borrow up to the continued outperformance of the wider market over the long lower of 120 million or 20% of the Companys net asset value.
In particular, they believe that the portfolio is well positioned to benefit from such factors as low valuations, a rise THE BOARD in the prospects for emerging markets, attractive growth Anthony Townsend, who has been a Director of the Company potential for large capitalisation pharmaceutical and since its launch in 1995, will be retiring from the Board at the biotechnology companies as a result of new product launches conclusion of this years Annual General Meeting.
Anthony was and continued merger and acquisition activity.
instrumental in ensuring the launch of the Company and I would Our focus continues to be on the selection of stocks with strong like to thank him for his hard work during his time on the Board.
prospects and we continue to believe that investors committed His experience and wise counsel will be greatly missed.
Jo Dixon to the sector will be well rewarded.
will be succeeding him as the Senior Independent Director.
I am delighted to welcome Sarah Bates onto the Board.
Sarah ANNUAL GENERAL MEETING brings with her a wealth of experience, both as a former This year, the Annual General Meeting of the Company will be Chairman of the Association of Investment Companies and also held at Carpenters Hall, Throgmorton Avenue, London as a non-executive Director of a number of public companies EC2N 2JJ on Wednesday, 17 July 2013 at 12 noon, and we hope including JPMorgan American Investment Trust plc, where she is as many shareholders as possible will attend.
This will be an Chairman, and also New India Investment Trust PLC, Polar Capital opportunity to meet the Board and to receive a presentation Technology Trust plc and Witan Pacific Investment Trust plc.
Sir Martin Smith Chairman 6June2013 Worldwide Healthcare Trust PLC Annual Report 2013
